FibroGen Inc. (NASDAQ:FGEN) traded down 1.1% during trading on Wednesday . The stock traded as low as $21.02 and last traded at $21.35, with a volume of 198,042 shares traded. The stock had previously closed at $21.59.

Separately, Credit Suisse Group AG reiterated a “buy” rating and issued a $37.00 price objective on shares of FibroGen in a research report on Tuesday, August 9th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $33.25.

The stock’s market cap is $1.37 billion. The stock’s 50-day moving average price is $18.97 and its 200-day moving average price is $18.45.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/fibrogen-inc-fgen-shares-down-1-1.html

FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.36 by $0.01. FibroGen had a negative return on equity of 48.66% and a negative net margin of 61.90%. Equities research analysts predict that FibroGen Inc. will post ($1.25) earnings per share for the current year.

In other FibroGen news, CEO Thomas B. Neff sold 37,798 shares of the stock in a transaction on Friday, August 26th. The stock was sold at an average price of $17.80, for a total value of $672,804.40. Following the sale, the chief executive officer now directly owns 3,403,639 shares of the company’s stock, valued at $60,584,774.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Thomas B. Neff sold 27,000 shares of the stock in a transaction on Wednesday, June 29th. The stock was sold at an average price of $16.02, for a total value of $432,540.00. Following the completion of the sale, the chief executive officer now directly owns 3,439,764 shares in the company, valued at $55,105,019.28. The disclosure for this sale can be found here. 14.90% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of FGEN. Sabby Management LLC bought a new stake in shares of FibroGen during the first quarter valued at $2,323,000. HBK Investments L P acquired a new position in shares of FibroGen during the first quarter worth approximately $528,000. State Street Corp raised its position in shares of FibroGen by 15.1% in the first quarter. State Street Corp now owns 1,330,809 shares of the biopharmaceutical company’s stock worth $28,335,000 after buying an additional 174,369 shares during the period. Landscape Capital Management L.L.C. raised its position in shares of FibroGen by 652.2% in the first quarter. Landscape Capital Management L.L.C. now owns 99,295 shares of the biopharmaceutical company’s stock worth $2,114,000 after buying an additional 86,095 shares during the period. Finally, Palisade Capital Management LLC NJ raised its position in shares of FibroGen by 6.3% in the first quarter. Palisade Capital Management LLC NJ now owns 55,350 shares of the biopharmaceutical company’s stock worth $1,178,000 after buying an additional 3,280 shares during the period. 49.82% of the stock is currently owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

5 Day Chart for NASDAQ:FGEN

Receive News & Ratings for FibroGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.